Assessing cost-effectiveness in the management of multiple sclerosis

@inproceedings{Phillips2009AssessingCI,
  title={Assessing cost-effectiveness in the management of multiple sclerosis},
  author={Ceri J. Phillips and Ioan Humphreys},
  booktitle={ClinicoEconomics and outcomes research : CEOR},
  year={2009}
}
Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults, with current prevalence rates estimated to be 30 per 100,000 populations. Women are approximately twice as susceptible as males, but males are more likely to have progressive disease. The onset of the disease normally occurs between 20 and 40… CONTINUE READING